📊 COGT Key Takeaways
Is Cogent Biosciences, Inc. (COGT) a Good Investment?
Cogent Biosciences faces severe operational distress with revenue collapsing 65% YoY to just $7.9M while operating losses reached $103.6M. The company is burning approximately $87M in free cash flow per quarter, exhausting its $241.2M cash reserve within 8-9 months, and shows no evidence of a viable path to profitability or revenue stabilization.
Cogent Biosciences shows weak current fundamentals, with very limited revenue, extreme negative operating and net margins, and large ongoing cash burn that indicates the business is still heavily dependent on external funding or existing balance-sheet reserves. The balance sheet is not distressed today because liquidity is strong and debt is moderate relative to equity, but growth quality is poor and the path to sustainable profitability remains highly uncertain.
Why Buy Cogent Biosciences, Inc. Stock? COGT Key Strengths
- Strong balance sheet with $241.2M cash and only $223.2M long-term debt (0.37x D/E ratio)
- Excellent liquidity with 15.14x current ratio providing near-term financial flexibility
- Moderate leverage allows potential for restructuring or asset-based financing
- Strong liquidity with $312.01M in cash and 14.23x current and quick ratios
- Equity base remains solid at $636.37M, limiting near-term balance sheet stress
- Debt load is manageable relative to equity at 0.35x
COGT Stock Risks: Cogent Biosciences, Inc. Investment Risks
- Catastrophic 65% YoY revenue decline indicates failed commercialization or major business disruption
- Operating cash burn of $86.9M per quarter with only 8-9 months of cash runway remaining
- Massive operating losses ($103.6M) and negative margins (-1316% operating margin) with no clear inflection point
- Existential risk of cash depletion unless dramatic operational turnaround or external financing materializes
- Revenue fell 65.0% YoY, indicating weak and potentially nonrecurring commercial traction
- Operating loss of $333.36M and free cash flow of -$266.00M reflect severe ongoing cash burn
- Net margin of -4179.1% shows the business is far from self-sustaining profitability
Key Metrics to Watch
- Quarterly revenue trend and product pipeline updates - any stabilization above $7.9M would be critical
- Monthly cash burn rate - deterioration below current levels indicates accelerated distress
- Major partnership or financing announcements - essential for extending runway beyond Q4 2026
- Quarterly operating cash burn relative to cash balance
- Revenue durability and improvement in operating loss trajectory
Cogent Biosciences, Inc. (COGT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.14x current ratio provides a solid financial cushion.
COGT Profit Margin, ROE & Profitability Analysis
COGT vs Healthcare Sector: How Cogent Biosciences, Inc. Compares
How Cogent Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cogent Biosciences, Inc. Stock Overvalued? COGT Valuation Analysis 2026
Based on fundamental analysis, Cogent Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cogent Biosciences, Inc. Balance Sheet: COGT Debt, Cash & Liquidity
COGT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cogent Biosciences, Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.94 indicates the company is currently unprofitable.
COGT Revenue Growth, EPS Growth & YoY Performance
COGT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $312.0K | -$6.1M | N/A |
| Q2 2021 | $528.0K | -$6.1M | N/A |
| Q1 2021 | $7.0M | -$6.1M | N/A |
| Q3 2020 | $312.0K | -$6.1M | N/A |
| Q2 2020 | $528.0K | -$6.1M | N/A |
| Q1 2020 | $3.1M | -$6.1M | N/A |
| Q3 2019 | $1.0M | -$6.7M | N/A |
| Q2 2019 | $1.7M | -$6.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cogent Biosciences, Inc. Dividends, Buybacks & Capital Allocation
COGT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cogent Biosciences, Inc. (CIK: 0001622229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COGT
What is the AI rating for COGT?
Cogent Biosciences, Inc. (COGT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COGT's key strengths?
Claude: Strong balance sheet with $241.2M cash and only $223.2M long-term debt (0.37x D/E ratio). Excellent liquidity with 15.14x current ratio providing near-term financial flexibility. ChatGPT: Strong liquidity with $312.01M in cash and 14.23x current and quick ratios. Equity base remains solid at $636.37M, limiting near-term balance sheet stress.
What are the risks of investing in COGT?
Claude: Catastrophic 65% YoY revenue decline indicates failed commercialization or major business disruption. Operating cash burn of $86.9M per quarter with only 8-9 months of cash runway remaining. ChatGPT: Revenue fell 65.0% YoY, indicating weak and potentially nonrecurring commercial traction. Operating loss of $333.36M and free cash flow of -$266.00M reflect severe ongoing cash burn.
What is COGT's revenue and growth?
Cogent Biosciences, Inc. reported revenue of $7.9M.
Does COGT pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
Where can I find COGT SEC filings?
Official SEC filings for Cogent Biosciences, Inc. (CIK: 0001622229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COGT's EPS?
Cogent Biosciences, Inc. has a diluted EPS of $-0.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COGT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Cogent Biosciences, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COGT stock overvalued or undervalued?
Valuation metrics for COGT: ROE of -16.0% (sector avg: 15%), net margin of -1,236.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy COGT stock in 2026?
Our dual AI analysis gives Cogent Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COGT's free cash flow?
Cogent Biosciences, Inc.'s operating cash flow is $-86.9M, with capital expenditures of $449.0K. FCF margin is -1,109.5%.
How does COGT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,236.8% (avg: 12%), ROE -16.0% (avg: 15%), current ratio 15.14 (avg: 2).